Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton Sells 83,660 Shares

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 83,660 shares of the business’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the sale, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. This represents a 10.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Biodesix Stock Performance

Shares of BDSX stock opened at $0.99 on Friday. The company has a market cap of $143.29 million, a P/E ratio of -2.53 and a beta of 1.06. The business has a 50 day moving average of $1.23 and a two-hundred day moving average of $1.48. Biodesix, Inc. has a 52 week low of $0.86 and a 52 week high of $2.04. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC lifted its stake in Biodesix by 8.8% in the fourth quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock valued at $9,455,000 after buying an additional 500,000 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Biodesix in the 3rd quarter valued at about $10,849,000. Birchview Capital LP grew its position in Biodesix by 0.7% in the 4th quarter. Birchview Capital LP now owns 5,581,176 shares of the company’s stock worth $8,539,000 after purchasing an additional 40,000 shares during the last quarter. Silverarc Capital Management LLC raised its holdings in shares of Biodesix by 21.7% during the fourth quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock valued at $6,628,000 after buying an additional 771,187 shares during the last quarter. Finally, Samjo Management LLC acquired a new position in shares of Biodesix during the fourth quarter worth approximately $3,790,000. 20.96% of the stock is currently owned by institutional investors.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.